| A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease M Sano, C Ernesto, RG Thomas, MR Klauber, K Schafer, M Grundman, ... New England Journal of Medicine 336 (17), 1216-1222, 1997 | 3471 | 1997 |
| Vitamin E and donepezil for the treatment of mild cognitive impairment RC Petersen, RG Thomas, M Grundman, D Bennett, R Doody, S Ferris, ... New England Journal of Medicine 352 (23), 2379-2388, 2005 | 2495 | 2005 |
| Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease RS Doody, RG Thomas, M Farlow, T Iwatsubo, B Vellas, S Joffe, ... New England Journal of Medicine 370 (4), 311-321, 2014 | 1767 | 2014 |
| An inventory to assess activities of daily living for clinical trials in Alzheimer's disease D Galasko, D Bennett, M Sano, C Ernesto, R Thomas, M Grundman, ... Alzheimer Disease & Associated Disorders 11, 33-39, 1997 | 1452 | 1997 |
| Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial RA Mulnard, CW Cotman, C Kawas, CH van Dyck, M Sano, R Doody, ... Jama 283 (8), 1007-1015, 2000 | 1310 | 2000 |
| A phase 3 trial of semagacestat for treatment of Alzheimer's disease RS Doody, R Raman, M Farlow, T Iwatsubo, B Vellas, S Joffe, K Kieburtz, ... New England Journal of Medicine 369 (4), 341-350, 2013 | 1298 | 2013 |
| Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials M Grundman, RC Petersen, SH Ferris, RG Thomas, PS Aisen, DA Bennett, ... Archives of neurology 61 (1), 59-66, 2004 | 1251 | 2004 |
| Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial PS Aisen, KA Schafer, M Grundman, E Pfeiffer, M Sano, KL Davis, ... Jama 289 (21), 2819-2826, 2003 | 1188 | 2003 |
| Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JF Quinn, R Raman, RG Thomas, K Yurko-Mauro, EB Nelson, C Van Dyck, ... Jama 304 (17), 1903-1911, 2010 | 896 | 2010 |
| Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. SG Ellis, GS Roubin, SB King 3rd, JS Douglas Jr, WS Weintraub, ... Circulation 77 (2), 372-379, 1988 | 884 | 1988 |
| Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study MA Raskind, ER Peskind, ED Kanter, EC Petrie, A Radant, CE Thompson, ... American Journal of Psychiatry 160 (2), 371-373, 2003 | 798 | 2003 |
| Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change LS Schneider, JT Olin, RS Doody, CM Clark, JC Morris, B Reisberg, ... Alzheimer Disease & Associated Disorders 11, 22-32, 1997 | 710 | 1997 |
| High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial PS Aisen, LS Schneider, M Sano, R Diaz-Arrastia, CH Van Dyck, ... Jama 300 (15), 1774-1783, 2008 | 647 | 2008 |
| The psychosocial impact of macular degeneration RA Williams, BL Brody, RG Thomas, RM Kaplan, SI Brown Archives of ophthalmology 116 (4), 514-520, 1998 | 646 | 1998 |
| A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease RS Turner, RG Thomas, S Craft, CH Van Dyck, J Mintzer, BA Reynolds, ... Neurology 85 (16), 1383-1391, 2015 | 644 | 2015 |
| A randomized controlled trial of prednisone in Alzheimer’s disease PS Aisen, KL Davis, JD Berg, K Schafer, K Campbell, RG Thomas, ... Neurology 54 (3), 588-588, 2000 | 639 | 2000 |
| The preclinical Alzheimer cognitive composite: measuring amyloid-related decline MC Donohue, RA Sperling, DP Salmon, DM Rentz, R Raman, ... JAMA neurology 71 (8), 961-970, 2014 | 622 | 2014 |
| High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype D Galasko, L Chang, R Motter, CM Clark, J Kaye, D Knopman, R Thomas, ... Archives of neurology 55 (7), 937-945, 1998 | 611 | 1998 |
| Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind … RS Doody, SI Gavrilova, M Sano, RG Thomas, PS Aisen, SO Bachurin, ... The Lancet 372 (9634), 207-215, 2008 | 608 | 2008 |
| Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), and apolipoprotein E receptor, with late-onset Alzheimer's disease DE Kang, T Saitoh, X Chen, Y Xia, E Masliah, LA Hansen, RG Thomas, ... Neurology 49 (1), 56-61, 1997 | 535 | 1997 |
Michael C Donohue, PhDAssociate Director of Biostatistics, Alzheimer's Therapeutic Research Institute, USC在 usc.edu 的电子邮件经过验证
